The Unravelling of Kodiak Sciences
Kodiak Sciences, Inc. (NASDAQ: KOD), a clinical-stage biotechnology Company focused on creating novel therapeutics for the treatment of retinal diseases, announced top-line results from a Phase 2b/3 clinical trial evaluating KSI-301, a novel antibody biopolymer conjugate, intended for the treatment of neovascular (wet) age-related macular...
